elezanumab
mAbexperimental
Elezanumab is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke. — Wikipedia
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02606630)
Timeline
Indications
Mechanism of action
- Repulsive guidance molecule AINHIBITOR
Repulsive guidance molecule A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaElezanumab ↗
- ChEMBLCHEMBL4297743 ↗
Also known as
- abt-555
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04295538 | Phase 2 | Jun 6, 2020 | AbbVie |
| NCT04309474 | Phase 2 | May 18, 2020 | AbbVie |
| NCT03737812 | Phase 2 | Feb 5, 2019 | AbbVie |
| NCT03737851 | Phase 2 | Dec 11, 2018 | AbbVie |
| NCT02601885 | Phase 1 | Oct 18, 2016 | AbbVie |
| NCT02606630 | Phase 1 | Oct 1, 2015 | AbbVie |
| NCT04278235 | N/A | — | AbbVie |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 3 | 2015 |
1 organizations
Page 1 / 1